Product Pipeline
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
- Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
- Braftovi® (encorafinib) + Mektovi® (binimetinib): BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
- Duchenne Muscular Dystrophy Gene Therapy
- fidanacogene elaparvovec (Gene Therapy, coagulation factor IX): Hemophilia
- giroctocogene fitelparvovec (Gene Therapy, coagulation factor VIII): Hemophilia
- Ibrance® (palbociclib): High Risk Early Breast Cancer
- Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
- Prophylactic Vaccine: Clostridioides difficile Infection Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal)
- Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata
- Talzenna® (talazoparib): Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
- Xeljanz® (tofacitinib): Ankylosing Spondylitis
- Xtandi® (enzalutamide): Metastatic Castration Sensitive Prostate Cancer, Non-Metastatic High Risk Castration Sensitive Prostate Cancer
Pipeline Snapshot as of July 28, 2020
- Discovery Projects
- 25Phase 1
- 38Phase 2
- 23Phase 3
- 4Registration
- Total90
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
PF-07081532 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Glucagon-like peptide 1 receptor (GLP-1R) Agonist | Diabetes Mellitus-Type 2, Obesity | Phase 1 | New Molecular Entity | Small Molecule |
PF-06826647 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2 Inhibitor | Ulcerative Colitis | Phase 1 | Product Enhancement | Small Molecule |
PF-06835375 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Chemokine Inhibitor | Lupus (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07038124 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical PDE4 Inhibitor | Atopic Dermatitis | Phase 1 | New Molecular Entity | Small Molecule |
PF-06842874 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 4,6 Inhibitor | Pulmonary Arterial Hypertension | Phase 1 | New Molecular Entity | Small Molecule |
PF-06882961 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Glucagon-like peptide 1 receptor (GLP-1R) Agonist | Diabetes Mellitus-Type 2, Obesity | Phase 1 | New Molecular Entity | Small Molecule |
PF-06946860 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Growth Factor Blocker | Cachexia (Biologic) | Phase 1 | New Molecular Entity | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) | Phase 1 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Cancer (Biologic) | Phase 1 | Product Enhancement | Biologic |
PF-05082566 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: CD137 Agonist | Combo w/Kite Pharma'sYescarta (axicabtagene ciloleucel)forCancer | Phase 1 | New Molecular Entity | Biologic |
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06753512 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Therapeutic Vaccine | Prostate Cancer | Phase 1 | New Molecular Entity | Vaccine |
PF-06804103 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: HER2 Antibody Drug Conjugate | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06821497 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: EZH2 inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-06863135 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: BCMA-CD3 Bispecific Antibody | Multiple Myeloma (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-06936308 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Therapeutic Vaccine | Multiple Cancers | Phase 1 | New Molecular Entity | Vaccine |
PF-06939999 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: protein arginine methyltransferase 5 (PRMT5) Inhibitor | Solid Tumors | Phase 1 | New Molecular Entity | Small Molecule |
